Immunotech Biopharm Ltd

Equities

6978

KYG4721A1004

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:12 2024-07-19 am EDT 5-day change 1st Jan Change
3.3 HKD +1.85% Intraday chart for Immunotech Biopharm Ltd +4.10% -34.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Immunotech Biopharm Unit Sells 80 Million Yuan of Certificates of Deposit MT
Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023 MT
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug MT
Immunotech Biopharm Receives an Approval of the Investigational New Drug Application for Phase I Clinical Trial from the Centre for Drug Evaluation of the National Medical Products Administration for the aT19 Injection CI
Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection CI
Chinese Drug Regulator Accepts Immunotech Biopharm's Application for AT19 Injection MT
Immunotech Biopharm Enrolls First Patient in Clinical Trial of Lymphoma Drug MT
Immunotech Biopharm Ltd Completes the First Patient Enrolment for its Phase I Clinical Trial for the Denocabtagene Ciloleucel Injection CI
China Grants Breakthrough Therapy Designation to Immunotech's Liver Cancer Medication; Shares Fall 5% MT
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Immunotech Biopharm Ltd Announces Board Changes CI
Immunotech Biopharm Ltd Announces Director Changes CI
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Immunotech Biopharm Obtains China Clinical Trial Approval for Lymphoma Treatment MT
Immunotech Biopharm Ltd Obtains the Clinical Approval for the Denocabtagene Ciloleucel Injection from the National Medical Products Administration CI
Immunotech Biopharm Extends Completion Date of Convertible Bond Sale MT
Immunotech Biopharm’s New Drug Application for Lymphoma Injection Accepted by Chinese Regulator MT
Immunotech Biopharm Ltd. Receives Acceptance Notice for the Investigational New Drug Application for the Denocabtagene Ciloleucel Injection CI
Immunotech Biopharm Shareholders to Meet on Convertible Bond Issuance MT
Immunotech Biopharm Ltd announced that it expects to receive CNY 300 million in funding from Tianjin Tasly Pharmaceutical Co., Ltd., Investment Arm CI
Immunotech Biopharm Sees $19.6 Million H1 Loss MT
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Immunotech Biopharm, NKY Medical Form Tumor Diagnostics JV in Shanghai MT
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Chart Immunotech Biopharm Ltd
More charts
Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 6978 Stock
  4. News Immunotech Biopharm Ltd
  5. Immunotech Biopharm Unit Sells 80 Million Yuan of Certificates of Deposit